By a News Reporter-Staff News Editor at Health& Medicine Week Allergan plc, a leading global pharmaceutical company, and ForSight VISION5, a privately held, clinical-stage biotechnology company focused on eye care, announced that they have entered into an agreement under which Allergan will acquire ForSight VISION5. Under the terms of the agreeme
STOCK EXCHANGE RELEASE 26 August 2016 at 2.30 p.m. Biotie: BTT1023 receives Orphan Drug Designation in the United States The United States Food and Drug Administration has granted Orphan Drug Designation in the United States for Biotie's BTT1023 drug candidate for the treatment of primary sclerosing cholangitis. The BUTEO study is conducted in...
-BirchBioMed Inc. announced today that a unique and ground-breaking topical treatment developed by University of British Columbia researchers to prevent scarring has completed a Health Canada approved Phase I trial. The study's findings will be released next week at the 2016 Congress of the International Society for Burn Injuries, the quadrennial..
-Health Center Gurus and Smartlink Mobile Systems today announced a strategic partnership to deliver a turnkey Chronic Care Management and Annual Wellness Visit solution for Federally Qualified Health Centers. The companies will be showcasing the solution in booth #1411 at the NACHC CHI& Expo, which is being held at the Hyatt Regency Chicago from A
Aug. 26 Illinois Attorney General Lisa Madigan has sued an Arizona drug company for allegedly pushing its powerful opioid painkiller, Subsys, beyond its intended use on cancer patients. The lawsuit claims Insys directed its sales and marketing efforts in Illinois to "high-volume opioid prescribers" who are not oncologists, including one Chicago d
By a News Reporter-Staff News Editor at Drug Week Instrumentation Laboratory introduced several key innovations in Hemostasis at the 68th AACC Annual Scientific Meeting& Clinical Lab Expo in Philadelphia, Pennsylvania, August 2-4. Giovanni Russi, Vice President of Worldwide Marketing and Service, outlined the new product offerings in a presentati
Release date- 25082016- CHESTERFIELD, United Kingdom- Mallinckrodt plc, a leading global specialty pharmaceutical company, today announced the U.S. Food and Drug Administration has granted the company's request for a Fast Track designation for its Investigational New Drug application for Synacthen Depot in the treatment of Duchenne muscular dystrop
Release date- 25082016- BENGALURU, India and HERTFORDSHIRE, England/ PITTSBURGH, USA- Mylan N.V. and Biocon Ltd. announced today that the European Medicines Agency has accepted for review Mylan's Marketing Authorization Application for a proposed biosimilar Trastuzumab, which is used to treat certain HER2-positive breast and gastric cancers.
The Centers for Medicare& Medicaid Services today announced the 2015 performance year results for the Medicare Shared Savings Program and the Pioneer Accountable Care Organization Model that show physicians, hospitals and health care providers participating in Accountable Care Organizations continue to make significant improvements in the quality
-PetLife Pharmaceuticals, Inc., a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce the signing of a contract with InnoVision Therapeutics, a major step towards the Center for Veterinary Medicine/ FDA testing and approval process for Vitalzul. We are pleased to be working
By a News Reporter-Staff News Editor at Health& Medicine Week Investigators publish new report on Hospitals. According to news reporting from Toronto, Canada, by NewsRx journalists, research stated, "One long-standing method for continuity of care as patients transition between the hospital and community are supportive visits by primary care phys
By a News Reporter-Staff News Editor at Drug Week New research on Lung Diseases and Conditions- Chronic Obstructive Pulmonary Disease is the subject of a report. According to news originating from Melbourne, Australia, by NewsRx correspondents, research stated, "Chronic obstructive pulmonary disease is a progressive, incurable illness, which lead
Scintilla Pharmaceuticals, a Subsidiary of Sorrento Therapeutics, to Acquire SCILEX Pharmaceuticals to Add a Late-Stage Asset to Bolster its Pain Management Business. By a News Reporter-Staff News Editor at Drug Week Scintilla Pharmaceuticals, Inc., a subsidiary of Sorrento Therapeutics, Inc., has entered into a binding term sheet to acquire SCIL
NEW YORK, Aug. 26, 2016 TG Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted orphan drug designation for TG-1101 the Company s novel, glycoengineered anti-CD20 monoclonal antibody, for the treatment of patients with neuromyelitis optica and neuromyelitis optica spectrum disorder. As demonstrated with th
San Francisco, CA 08/26/2016 TheraKine Ltd. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 86310619, a key patent for its innovative sustained-release formulation of injectable drugs. CEO Seth Yakatan says, "We believe we are the only company that offers months of linear release without polymers
About 30 million Americans seek chiropractic care annually, and apparently not all of them know their visits are routinely covered by major medical insurance carriers, Medicare, workers' compensation, and even some Medicaid plans. Part of the increased availability is a result of non-discrimination measures in the Patient Protection and Affordable
SUMMARY: The Food and Drug Administration is announcing the availability of a guidance for industry entitled "Abbreviated New Drug Application SubmissionsRefuse to Receive for Lack of Justification of Impurity Limits." This guidance is intended to assist applicants preparing to submit to FDA abbreviated new drug applications and prior approval...
Advanced Clinical Laboratory Solutions, Inc., an independent clinical laboratory specializing in clinical toxicology and pharmacogenetics that provides convenient, high-quality testing services and accurate, timely test results to patients, physicians and medical centers across the country, has signed a clinical laboratory services contract...
Alexander Nachman, America's "Pitbull of Pot" and expert on the cannabis industry, wrote about the hypocrisy of the United States Government's stance on medical marijuana. Synthetic THC has been FDA approved since 1985 and is currently listed as a Schedule III drug. Ironically, the DEA just ruled that Marijuana the actual plant will remain
Brian Scott, Chief Financial Officer of AMN Healthcare, will be presenting at the conference. About AMN Healthcare AMN Healthcare is the leader and innovator in healthcare workforce solutions and staffing services to healthcare facilities across the nation. With insights and expertise, AMN Healthcare helps providers optimize their workforce to...
We and Eisai Inc. have received a "Paragraph IV certification" notification with respect to patents for BELVIQ listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The certification was from an Abbreviated New Drug Application for a proposed generic version of BELVIQ . In accordance with the.
Infosys, Ally Connected Care, m Health Alert, Propeller, toSense, Science Soft, Health Smart, Alberta Health Services, AFFINIA Healthcare. Market Research Future PUNE, MAHARASHTRA, INDIA, August 25, 2016/ EINPresswire.com/ Study Objectives of Chronic Diseases Management Market:? To provide detailed analysis of the market structure along with
In the letter, Congressman Bera asks the FDA to address processes that may limit competition and allow some companies to drastically increase prices. That's why I'm calling on the FDA to make sure that families have other more affordable and safe options to EpiPens so that no one needs to make a choice between paying their bills or having a life-sa
-Corium International, Inc., a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced receiving favorable written feedback from the U.S. Food and Drug Administration on the companys Pre-Investigational New Drug Application submission for...